Literature DB >> 6652973

Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen.

R R Freeman, A A Holder.   

Abstract

The response of BALB/c mice to immunization with a 230,000 mol. wt protective antigen purified from the blood stages of Plasmodium yoelii was analysed. The protective response to immunization was adjuvant-dependent, and saponin was found to be the most effective adjuvant tested. The intraperitoneal route was found to be superior to the subcutaneous route for protective immunization. Maximal protection was achieved using two immunizations with greater than 12.5 micrograms of antigen plus saponin, but even under these conditions challenge infection developed normally for 5 days, followed by the appearance of crisis forms and rapid clearance of parasites. Effective immunization induced high antibody titres, but serum from immunized mice was not protective on passive transfer. On the other hand, hyperimmune serum from mice recovered and rechallenged with live P. yoelii was protective on passive transfer, even though the titre of antibody specific for the 230,000 mol. wt antigen in this serum was the same as that in the serum from mice immunized with the purified antigen. It was concluded that the 230,000 mol. wt antigen may provide protection against P. yoelii via the cell-mediated immune effector pathway described by Playfair et al. (1979), and that hyperimmune serum contains protective antibodies specific for P. yoelii antigens other than the 230,000 mol. wt antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652973      PMCID: PMC1536166     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Protection of mice against malaria by a killed vaccine: differences in effectiveness against P. yoelii and P. berghei.

Authors:  J H Playfair; J B De Souza; B J Cottrell
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

2.  Immunization against blood-stage rodent malaria using purified parasite antigens.

Authors:  A A Holder; R R Freeman
Journal:  Nature       Date:  1981-11-26       Impact factor: 49.962

3.  Plasmodium yoelii: antibody and the maintenance of immunity in BALB/c mice.

Authors:  R R Freeman; C R Parish
Journal:  Exp Parasitol       Date:  1981-08       Impact factor: 2.011

4.  Cell-mediated immunity in mice vaccinated against malaria.

Authors:  B J Cottrell; J H Playfair; B J De Souza
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

5.  Immunity to Plasmodium chabaudi adami in the B-cell-deficient mouse.

Authors:  J L Grun; W P Weidanz
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

6.  Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria.

Authors:  I A Clark; N H Hunt
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Protective monoclonal antibodies recognising stage-specific merozoite antigens of a rodent malaria parasite.

Authors:  R R Freeman; A J Trejdosiewicz; G A Cross
Journal:  Nature       Date:  1980-03-27       Impact factor: 49.962

8.  Cell-mediated immunity in the liver of mice vaccinated against malaria.

Authors:  J H Playfair; J B De Souza; H M Dockrell; P U Agomo; J Taverne
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

9.  Antibody responses in mice protected against malaria by vaccination.

Authors:  J H Playfair; J B De Souza
Journal:  Parasite Immunol       Date:  1979       Impact factor: 2.280

  9 in total
  23 in total

1.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

3.  The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody.

Authors:  J M Burns; T M Daly; A B Vaidya; C A Long
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

4.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

5.  Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice.

Authors:  J H Playfair; J B De Souza
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

6.  Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice.

Authors:  Upma Bagai; Anil Pawar; Vineet Kumar
Journal:  J Parasit Dis       Date:  2010-10-08

7.  Two soluble antigens of Plasmodium falciparum induce tumor necrosis factor release from macrophages.

Authors:  J Taverne; C A Bate; D Kwiatkowski; P H Jakobsen; J H Playfair
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

8.  Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

Authors:  S Kumar; A Yadava; D B Keister; J H Tian; M Ohl; K A Perdue-Greenfield; L H Miller; D C Kaslow
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

9.  Roles of the Maltese cross form in the development of parasitemia and protection against Babesia microti infection in mice.

Authors:  Naoaki Yokoyama; Sabine Bork; Mitsuhiro Nishisaka; Haruyuki Hirata; Tomohide Matsuo; Noboru Inoue; Xuenan Xuan; Hiroshi Suzuki; Chihiro Sugimoto; Ikuo Igarashi
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 10.  Malaria vaccine development.

Authors:  T R Jones; S L Hoffman
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.